Aptevo Therapeutics Inc. 在一份提交给美国证券交易委员会的文件中披露,一项修订已将优先股千分之一份额的购买价格调整为14.56美元。
Aptevo Therapeutics Inc. 在一份提交给美国证券交易委员会的文件中披露,一项修订已将优先股千分之一份额的购买价格调整为14.56美元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.